Efficacy, safety and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

CONCLUSIONS: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.PMID:38190830 | DOI:10.3350/cmh.2023.0422

Source: Clinical and molecular hepatology - January 8, 2024 Category: Gastroenterology Authors: Jinlin Hou Edward Gane Rozalina Balabanska Wenhong Zhang Jiming Zhang Tien Huey Lim Qing Xie Chau-Ting Yeh Sheng-Shun Yang Xieer Liang Piyawat Komolmit Apinya Leerapun Zenghui Xue Ethan Chen Yuchen Zhang Qiaoqiao Xie Ting-Tsung Chang Tsung-Hui Hu Seng Gee Source Type: research